Altor BioScience Corporation

In an unscripted moment of synchronicity, the complete response letter for linvoseltamab announced by Regeneron Pharmaceuticals, Inc. on 20 August exemplified the findings of a US Food and Drug Admi

The US Food and Drug Administration approvals of Day One Biopharmaceuticals, LLC ’s Ojemda (tovorafenib) and ImmunityBio Inc. ’s Anktiva (nogapendekin alfa inbakicept-pmln) last week provided a boos

New York-based biotech UroGen Pharma Ltd. reported positive top-line Phase III clinical results with its lead compound, UGN-101 (mitomycin gel, 0.4%), in patients with low-grade upper tract urotheli

President Obama’s final State of the Union address could not have set a better tone for the year ahead for the innovator biopharmaceutical industry. The direct impact of any State of the Union address